DOJ Begins Cannabis Rescheduling Process Under Trump Administration
Acting Attorney General initiates move to reclassify cannabis from Schedule I to Schedule III, delivering on campaign promise with major industry implications.
The Department of Justice has begun the formal process to reschedule cannabis from Schedule I to Schedule III, marking the first concrete regulatory action under the Trump administration's renewed approach to federal cannabis policy. The Acting Attorney General's directive represents a departure from previous enforcement priorities and signals potential federal-level reform that could reshape the entire cannabis sector.
Rescheduling cannabis to Schedule III would fundamentally alter the financial landscape for cannabis operators by eliminating the punitive 280E tax provision that currently prevents companies from deducting standard business expenses. This change could dramatically improve profit margins across the industry, with analysts estimating potential tax savings of 20-40% for major multi-state operators like Curaleaf Holdings (CURLF), Green Thumb Industries (GTBIF), and Trulieve Cannabis (TCNNF).
The regulatory shift comes as the cannabis industry faces mounting pressure from oversupply in key markets and compressed margins due to increased competition. Schedule III classification would provide immediate financial relief while maintaining federal oversight through prescription drug regulations. However, the rescheduling process requires coordination between multiple federal agencies and could face legal challenges that extend implementation timelines.
Industry operators have responded positively to the DOJ's initiative, viewing it as validation of the sector's evolution toward mainstream acceptance. The move aligns with broader state-level legalization trends, where 38 states now permit medical cannabis and 21 allow adult-use programs. Federal rescheduling could accelerate interstate commerce opportunities and banking access that have remained elusive under current Schedule I restrictions.
The rescheduling announcement arrives at a critical juncture for cannabis markets, with sector valuations remaining depressed despite growing state-level sales volumes. Federal policy clarity could catalyze institutional investment and improve access to traditional capital markets, potentially triggering a revaluation of cannabis assets that have traded at significant discounts to other consumer discretionary sectors.